Management of obesity and cardiometabolic risk – role of phentermine/extended release topiramate
Arianne N Sweeting,1 Eddy Tabet,1 Ian D Caterson,1,2 Tania P Markovic1,2 1Department of Endocrinology, Royal Prince Alfred Hospital, Sydney, NSW, Australia; 2Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, University of Sydney, NSW, Australia Abstract: The US Food and D...
Enregistré dans:
Auteurs principaux: | Sweeting AN, Tabet E, Caterson ID, Markovic TP |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Dove Medical Press
2014
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/a56e0dd14d9f45b49aa2b9cff1739cda |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Clinical utility of phentermine/topiramate (Qsymia™) combination for the treatment of obesity
par: Shin JH, et autres
Publié: (2013) -
Effects of Orlistat/Phentermine versus Phentermine on Vascular Endothelial Cell Function in Obese and Overweight Adults: A Randomized, Double-Blinded, Placebo-Controlled Trial
par: Kwon YJ, et autres
Publié: (2021) -
Prevalence of cardiometabolic risk factors and metabolic syndrome in obese Kuwaiti adolescents
par: Boodai SA, et autres
Publié: (2014) -
Challenging obesity, diabetes, and addiction: the potential of lorcaserin extended release
par: Hurt RT, et autres
Publié: (2018) -
Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
par: Stolar MW, et autres
Publié: (2013)